Ben-Tov Amir, Achler Tomer, Patalon Tal, Gazit Sivan, Yanai Henit, Shulman Shiri, Assa Amit
Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
Pediatric Gastroenterology Institute, Dana-Dwek Children's Hospital, Tel Aviv, Israel.
Inflamm Bowel Dis. 2025 May 12;31(5):1256-1262. doi: 10.1093/ibd/izae160.
Ocular manifestations (OMs) in patients with inflammatory bowel disease (IBD) are uncommon, particularly in children. We aimed to explore the prevalence and characteristics of IBD-associated OM in a large cohort study.
A cross-sectional study was performed using the Maccabi Healthcare Services (MHS) database. The eligible population included all patients diagnosed with IBD as children (<18 years) between January 2005 and July 2023.
Out of 2567 children with IBD (males 55%, Crohn's disease 64%), 78 (3%) were diagnosed with OM at any time during the disease course. In 54 patients (69%), the ocular disease occurred after IBD diagnosis with a median time of 2.6 (0.47-7) years between the 2 events, whereas in 24 patients (31%), ocular involvement preceded IBD diagnosis with a median time of 2.1 (0.6-5.7) years. The presence of ocular involvement was associated with increased usage of systemic corticosteroids (P < .001) and biologic agents (P = .04). There were 55 patients with ocular involvement during childhood who were ever diagnosed with IBD. In this population, ocular involvement was also associated with increased usage of systemic corticosteroids (P < .001). The prevalence of OM among patients with IBD did not change significantly over time (P = .75), with a prevalence of 2.3% at the end of the study period.
The prevalence of ocular involvement in children with IBD is rare and steady; it is also associated with a greater usage of systemic corticosteroids and biologic agents, potentially representing a more severe disease course.
炎症性肠病(IBD)患者的眼部表现(OMs)并不常见,尤其是在儿童中。我们旨在通过一项大型队列研究探讨IBD相关OMs的患病率和特征。
使用马卡比医疗服务(MHS)数据库进行横断面研究。符合条件的人群包括2005年1月至2023年7月期间所有在儿童期(<18岁)被诊断为IBD的患者。
在2567例IBD儿童患者中(男性占55%,克罗恩病占64%),78例(3%)在病程中的任何时候被诊断为OMs。在54例患者(69%)中,眼部疾病在IBD诊断后出现,这两个事件之间的中位时间为2.6(0.47 - 7)年,而在24例患者(31%)中,眼部受累先于IBD诊断,中位时间为2.1(0.6 - 5.7)年。眼部受累与全身用皮质类固醇的使用增加相关(P <.001)以及生物制剂的使用增加相关(P =.04)。有55例儿童期有眼部受累的患者曾被诊断为IBD。在这一人群中,眼部受累也与全身用皮质类固醇的使用增加相关(P <.001)。IBD患者中OMs的患病率随时间没有显著变化(P =.75),在研究期末患病率为2.3%。
IBD儿童患者中眼部受累的患病率很低且稳定;它还与全身用皮质类固醇和生物制剂的更多使用相关,这可能代表着更严重的病程。